Emerging Therapies Plaque Psoriasis

The latest set of guidelines for psoriasis being developed by the American Academy of Dermatology and the National Psoriasis Foundation will stress patient education and the need to align treatment strategies with patient lifestyles.

The latest American Academy of Dermatology-National Psoriasis Foundation phototherapy guidelines incorporate several advances in efficacy, safety and patient convenience that were unavailable a decade ago.

When it comes to biologic drugs, the latest joint American Academy of Dermatology-National Psoriasis Foundation guidelines are less prescriptive than descriptive, offering a comprehensive discussion on the facts of each biologic to inform physicians’ selections.

Dermatologists often combine multiple topical agents on their own, and have been doing so for many years. However, extemporaneous compounding of psoriasis topical agents may not necessarily yield what dermatologists anticipate.

New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium.

With extended remissions, high safety and favorable dosing schedules, interleukin (IL)-23 inhibitors are well-suited for a variety of patients with psoriasis, says an expert who spoke at the South Beach Symposium

Risankizumab (SKYRIZI, AbbVie), outperformed secukinumab (Cosentyx, Novartis) in a head-to-head phase 3 study comparing the two treatments in adult patients with moderate to severe plaque psoriasis, according to data released by the company Jan. 14.

Topical halobetasol propionate 0.01% lotion appears to safely and quickly improve lower-extremity psoriatic lesions, according to a recent study.